CLINUVEL Strategic Update II
Melbourne, Australia, 12 April 2021 CLINUVEL today announced its second Strategic Update,...
Read More
CLINUVEL Kommuniqué II
Liebe Aktionäre, Freunde Wir begrüßen viele neue Aktionäre, insbesondere die große Anzahl...
Read More
CLINUVEL Communiqué II
Dear shareholders, friends We welcome many new shareholders, especially the large number...
Read More
Chair's Letter I
Direction and horizon In the last weeks, I have had investor questions...
Read More
Media Release - CLINUVEL Expands DNA Repair Program
SCENESSE® (afamelanotide 16mg) to be evaluated in xeroderma pigmentosum variant (XP-V) CLINUVEL...
Read More
SCENESSE® To Be Evaluated in Xeroderma Pigmentosum Variant (XPV)
CLINUVEL today announced that it has reached agreement with clinical and academic...
Read More
Investor Presentation - Daiwa Investment Conference Tokyo 2021
10 March 2021 – Melbourne, Australia On 10 March 2021 CLINUVEL presented...
Read More
Appendix 3Y Change of Director's Interest Notice
CLINUVEL PHARMACEUTICALS LTD today released the attached Appendix 3Y which relates to...
Read More
Appendix 3Y Change of Director's Interest Notice
Information or documents not available now must be given to ASX as...
Read More
SCIENTIFIC COMMUNIQUÉ IX
Beyond Pigment, the Melanocortin 1 Receptor (MC1R) in DNA Repair March 2021...
Read More
Operations Update Webinar
https://vimeo.com/516430955/8f3e88ca5chttps://vimeo.com/516430955/8f3e88ca5c
Read More
CLINUVEL Reports Tenth Consecutive Half Year Net Profit
KEY HIGHLIGHTS, HALF YEAR ENDED 31 DECEMBER 2020 Consolidated Entity Result Change...
Read More
Appendix 4D Half Year Report
Results For Announcement To The Market ($A’000) Revenues from continuing activities Increased...
Read More
Financial Results Half Year Ended 31 December 2020
Operations Update I Webinar CLINUVEL PHARMACEUTICALS LTD CLINUVEL PHARMACEUTICALS LTD will host...
Read More
SCENESSE® Granted Market Access In Israel
CLINUVEL today announced that SCENESSE® (afamelanotide 16mg) has been added to the...
Read More